العلاج الخطي الأول لورم الظهارة المتوسطة الجنبية حديث التشخيص ذو النسيج الظهاري

References

• In patients with newly diagnosed epithelioid mesothelioma, ipilimumab plus nivolumab immunotherapy should be offered as a first-line systemic treatment option.
• Ipilimumab plus nivolumab immunotherapy should be administered for a duration up to 2 years in the absence of disease progression or intolerable toxicity.
• In patients with epithelioid histology, pemetrexed plus platinum-based chemotherapy with or without bevacizumab may be offered as a first-line systemic treatment option.